Anti-c-Met and Anti-Ang-2 Antibody Combination Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-Ang-2 antibody therapies for inhibiting angiogenesis can promote cancer metastasis due to hypoxia-induced up-regulation of Ang-2, and they often require higher doses, leading to side effects and reduced patient convenience.
Innovation Solution
A combination therapy using an anti-c-Met antibody and an anti-Ang-2 antibody, administered simultaneously or sequentially, to inhibit angiogenesis and suppress cancer growth and metastasis, potentially allowing for lower doses and reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-Ang-2 antibody is used to inhibit angiogenesis, then angiogenesis is suppressed, but cancer metastasis is promoted due to hypoxia-induced up-regulation of Ang-2
Solution Approach 1:
The patent combines anti-Ang-2 antibody with anti-c-Met antibody to create a combination therapy. The anti-c-Met antibody blocks the c-Met receptor that mediates hypoxia-induced Ang-2 up-regulation, thereby preventing the harmful metastatic effect while maintaining the beneficial anti-angiogenic effect of the anti-Ang-2 antibody.
Solution Approach 2:
The anti-c-Met antibody acts as an intermediary that blocks the harmful signaling pathway (c-Met/HGF axis) responsible for hypoxia-induced Ang-2 up-regulation. This intermediary blocks the mechanism by which single anti-Ang-2 therapy fails, preventing metastasis without compromising anti-angiogenesis.
2Reliability
If higher dose of anti-Ang-2 antibody is administered to improve therapeutic effect, then angiogenesis inhibition is enhanced, but side effects increase and patient convenience is reduced
Solution Approach 1:
By combining two antibodies with complementary mechanisms of action (anti-Ang-2 blocking vascular endothelial growth and anti-c-Met blocking hypoxia-induced signaling), the therapy achieves enhanced therapeutic effect at lower individual doses, thereby reducing side effects and improving patient convenience.
Solution Approach 2:
The combination therapy changes the dosing parameters by allowing lower doses of each individual antibody to achieve the same or better therapeutic effect compared to high doses of single antibody therapy, thus reducing toxicity and improving quality of life.
Data Source
AI summary
A method for inhibiting angiogenesis and treating angiogenesis related diseases comprising administering an anti-c-Met antibody or an antigen-binding fragment thereof, and an anti-Ang-2 antibody or an antigen-binding fragment thereof, in combination simultaneously or sequentially; as well as related compositions and methods.